Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04951076 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)
A Phase 2 study of Post Traumatic Stress Disorder, sponsored by Bionomics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
- 20
- Study locations
NCT04951076: Completed Phase 2 study of Post Traumatic Stress Disorder, sponsored by Bionomics Limited.
NCT04951076 is a Phase 2 study of Post Traumatic Stress Disorder that has completed, run by Bionomics Limited. The registered enrollment target is 212 participants, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04951076, a Phase 2 study of Post Traumatic Stress Disorder, has completed, sponsored by Bionomics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the effects of BNC210 compared to placebo on Post-Traumatic Stress Disorder (PTSD) symptom severity as measured by the Clinician Administered PTSD scale for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom Severity Scores.
Primary Outcome
The CAPS-5 is a 30-item structured interview used to diagnose PTSD and assess PTSD symptoms over the past month. Information about the frequency and intensity of each item is combined into a severity rating, and the CAPS-5 total symptom severity score is calculated by adding the severity scores for the 20 PTSD symptoms in the DSM-5. Scores range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BNC210
Study Locations (20)
California
- ATTUNE Study Clinical Trial Site - Bellflower
- ATTUNE Study Clinical Trial Site - Beverly Hills
- ATTUNE Study Clinical Trial Site - Colton
- ATTUNE Study Clinical Trial Site - Oceanside
- ATTUNE Study Clinical Trial Site - Orange
- ATTUNE Study Clinical Trial Site - Temecula
Florida
- ATTTUNE Study Clinical Trial Site - Jacksonville
- ATTUNE Study Clinical Trial Site - Lauderhill
- ATTUNE Study Clinical Trial Site - Miami Lakes
- ATTUNE Study Clinical Trial Site - Orlando
Kansas
- ATTUNE Study Clinical Trial Site - Overland Park
- ATTUNE Study Clinical Trial Site - Prairie Village
New Jersey
- ATTUNE Study Clinical Trial Site - Berlin
- ATTUNE Study Clinical Trial Site - Cherry Hill
New York
- ATTUNE Study Clinical Trial Site - Cedarhurst
- ATTUNE Study Clinical Trial Site - Staten Island
Massachusetts
- ATTUNE Study Clinical Trial Site - New Bedford
Nevada
- ATTUNE Study Clinical Trial Site - Las Vegas
Ohio
- ATTUNE Study Clinical Trial Site - North Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2023-08-14 |
| Phase | Phase 2 |
What the finished NCT04951076 record still lists
NCT04951076 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04951076 names 20 study sites across 9 states, led by California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT04951076 about?
NCT04951076 is a clinical study titled "A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)". The purpose of this study is to assess the effects of BNC210 compared to placebo on Post-Traumatic Stress Disorder (PTSD) symptom severity as measured by the Clinician Administered PTSD scale for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom ...
What is the current status of trial NCT04951076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2021-07-27. Estimated completion is 2023-08-14.
What conditions does trial NCT04951076 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT04951076?
The interventions under investigation include: Placebo (DRUG), BNC210 (DRUG).
Who is sponsoring clinical trial NCT04951076?
This trial is sponsored by Bionomics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04951076 being conducted?
This trial has 20 study locations across California, Florida, Kansas, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04951076's enrollment target sits among peer trials
212 45th of 262 higher than 218 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
RECRUITING · Phase 2
-
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
RECRUITING · Phase 2
-
MDMA for AUD/PTSD Comorbidity
RECRUITING · Phase 2
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI